Forecast

The analysts' average price target is €258.21 (+10.77%). The median is €250.62 (+7.52%).

Buy
  12
Hold
  2
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Steris builds $600 million production center in North Carolina

    Steris announces a $600 million investment for a new 600,000-square-foot manufacturing and distribution center near the Raleigh-Durham Research Triangle. Upon completion, the company will relocate its chemical operations from St. Louis and Plymouth to the new site, which will produce chemicals for infection prevention and contamination control. The facility is expected to be operational in two to three years, with distribution activities starting earlier; about 335 jobs will be created. The investment is supported by state and local incentive programs. » More on de.investing.com


  • STERIS raises dividend for 2026 to $2.46 per share

    At the annual general meeting a dividend of $2.46 per share was approved for 2026, an increase of 10.31% versus the previous year. In total STERIS will pay out $241.80 million, raising the payout by 9.97% and resulting in a dividend yield of 1.11% (previously 0.98%). FactSet expects an increase to $2.58 for 2027 (dividend yield 1.13%); the share price closed at $228.40 on the day of the meeting and is currently trading ex-dividend. » More on finanzen.net


  • STERIS: one-year loss of 5.34 percent for investors

    Had $10,000 been invested in STERIS one year ago, the 44.705 shares on July 21, 2026 would have been worth $9,466.23, representing a loss of 5.34 percent. The closing price on July 21, 2026 was $211.75; a year earlier it was $223.69. STERIS's market capitalization most recently stood at $20.90 billion. » More on finanzen.net


  • STERIS Q4 2026: revenue beats expectations, EPS slightly below forecast

    STERIS reported Q4 2026 revenue of USD 1.6 billion, beating expectations, while earnings per share of USD 2.83 narrowly missed the analysts’ estimate of USD 2.85. For fiscal 2026 the company posted record revenue of USD 6.0 billion, adjusted EPS growth of 10% and free cash flow of USD 982.9 million. The EBIT margin improved slightly despite tariffs and inflation, and management forecasts further revenue and earnings growth for 2027 (revenue guidance USD 6.32 billion, EPS USD 11.23). The stock reacted positively and rose in after-hours trading, signaling investor confidence in the outlook. » More on de.investing.com


  • STERIS beats revenue forecasts in Q4, slightly misses EPS

    STERIS reported Q4 FY2026 revenue of $1.60bn, beating expectations; adjusted EPS was $2.83, missing the estimate by $0.02. Revenue rose 7% year-on-year (organic +5%) despite margin pressure from inflation and tariffs; gross margin slipped slightly to 44% and the EBIT margin reached 24.2%. The stock fell about 2.2% pre-market; the company gave an FY2027 EPS target of $10.27–11.23 and revenue guidance of $5.943–6.324bn. Management cites operational efficiency, acquisitions and product innovation as core drivers, but warns of ongoing cost risks and geopolitical disruptions. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Steris has already paid €1.70 in dividends. The last payout was in September.

Financials

In the last quarter, Steris had revenue of €1.4B and net profit of €188.67M

(EUR) September 2026
YoY
Revenue 1.4B 12.71%
Gross profit 627.53M 14.02%
Net profit 188.67M 15.37%
EBITDA 264.15M 20.46%

Fundamentals

Metric Value
Market capitalization
€22.63B
Number of shares
97.11M
52-week high/low
€245.55 - €177.84
Dividend yield
0.94%
Dividends TTM
€2.24
Next dividend
€0.63
Beta
0.87
P/E ratio
30.27
PEG ratio
1.45
P/B ratio
3.43
P/S ratio
4.03

Company profile

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

Name
Steris
CEO
Daniel A. Carestio
Headquarters Mentor, oh
Ireland
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
06/01/1992
Employees 17,937

Ticker symbols

Exchange Symbol
NYSE
STE
London
0XI8.L
🍪

Parqet  uses cookies. Learn more